Policymakers more often request outcomes research for expensive therapies to help resolve uncertainty of their health benefits and budget impact at reimbursement. Given the limitations of observational data, we assessed its usefulness in evaluating clinical outcomes for bortezomib in advanced...

To investigate the desirability and feasibility of a cyclic reimbursement process to address uncertainty accompanying initial decision making.